SCHEDULE: RA Capital Discloses 9.9% Stake in Monopar Therapeutics
Beneficial Ownership Disclosure (Schedule 13G Amendment)
RA Capital Management and its affiliates reported a 9.9% beneficial ownership stake in Monopar Therapeutics Inc., primarily through common stock and pre-funded warrants.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13G.
- The Reporting Persons beneficially own an aggregate of 742,861 shares of Monopar Therapeutics Inc. common stock.
- This represents 9.9% of the class of securities, rounded down from 9.99% due to EDGAR filing system limitations.
- The ownership includes 511,207 shares of Common Stock directly held by RA Capital Healthcare Fund, L.P. and Pre-Funded Warrants exercisable for up to 1,621,640 shares of Common Stock.
- A "Beneficial Ownership Blocker" provision in the Pre-Funded Warrants prevents exercise if it would result in ownership exceeding 9.99% of outstanding Common Stock.
- The percentage is calculated based on 6,169,961 shares outstanding as of July 31, 2025, plus 1,034,433 shares from a public offering, and 231,654 shares issuable from Pre-Funded Warrants.
- The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G and disclaim beneficial ownership of the securities for any purpose other than determining their obligations under Section 13(d) of the Act.
Sentiment
Score: 5
Explanation: Neutral. This is a routine disclosure of beneficial ownership by an institutional investor, providing factual information without expressing positive or negative sentiment about the issuer's performance or prospects.
Future Outlook
No forward-looking statements or guidance are provided by the reporting persons in this beneficial ownership disclosure.
Industry Context
This filing indicates continued institutional investment by a healthcare-focused fund (RA Capital) in a biotechnology company (Monopar Therapeutics). Such disclosures are common for active investors in the biotech sector, reflecting their portfolio positions and adherence to regulatory reporting requirements.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed as a vote of confidence or as a factor in market liquidity.
- Company Management: Awareness of a significant institutional holder may influence strategic decisions or engagement.
Key Dates
| Date | Description |
|---|---|
| 2025-07-31 | Date of outstanding shares reported in Issuer's Quarter Report on Form 10-Q. |
| 2025-08-12 | Date Issuer's Quarter Report on Form 10-Q was filed with the SEC. |
| 2025-09-24 | Date Issuer's Prospectus Supplement for public offering was filed with the SEC. |
| 2025-09-30 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-11-14 | Date of signing for the Schedule 13G/A filing. |
Keywords
Monopar Therapeutics, RA Capital Management, Schedule 13G, beneficial ownership, common stock, pre-funded warrants, institutional ownership, biotech investment, healthcare fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.